Recently, through in silico binding assay and the CMap approach AZ-628, a potent RIPK3 antagonist was discovered, which seemed to modulate TRIM24-RIPK3 axis and targeted RIPK3-kinase activity, resulting in reduced osteoarthritis pathogenesis in the DMM mice model [208]. The gene discussed is RIPK3; the disease is osteoarthritis.